Dublin, Feb. 05, 2020 (GLOBE NEWSWIRE) — The “North American Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT – Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), Application (Oncology, Cardiology) – Forecasts to 2024” report has been added to ResearchAndMarkets.com's offering.
The North American nuclear medicine market is projected to reach USD 2.7 billion by 2024 from an estimated USD 2.2 billion in 2019, growing at a CAGR of 4.1% during the forecast period.
The market has witnessed various advancements in products and their approvals to meet the needs of patients and radiologists worldwide. Growth in the market can primarily be attributed to factors such as increasing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99.
Cardinal Health (US), GE Healthcare (US), and Curium (France) were the leading players in the North American nuclear medicine market.
The Technetium-99m segment to hold the largest share of the SPECT radiopharmaceuticals market in 2019
Based on type, the SPECT Radiopharmaceuticals market is segmented into Tc-99m, Tl-201, Ga-67, I-123, and other isotopes. In 2019, the Tc-99m segment is expected to hold the largest share of the SPECT radiopharmaceuticals market. The large share of this segment can be attributed to the fact that Tc-99m is the most commonly used diagnostic radioisotope, which is used in around 80-90% of diagnostic scans and around 30 million patient examinations every year.
The endocrine tumours segment is projected to grow at the highest CAGR during the forecast period
Based on application, the North American nuclear medicine market is categorized into thyroid indications, bone metastasis, lymphoma, endocrine tumours, and other indications. The endocrine tumours segment is expected to be the fastest-growing application segment in the therapeutic nuclear medicine applications market. The growth in this segment is majorly driven by the increasing use of therapeutic radiopharmaceuticals in the treatment of endocrine tumours.
The US to witness the highest growth during the forecast period
The North American nuclear medicine market is segmented into the US and Canada, …
Disclaimer: All posts made on this website are provided for information purposes only. None of the information here is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, Company, or fund. Before making an investment decision, you should seek the advice of a qualified and registered securities professional. The author is not paid to share this information. Cannabis Investment Group is not paid to share this information and has no business relationship other than shareholder with any company whose stock is mentioned in this article.